Insight Molecular Diagnostics Inc. (IMDX): auditor change — Oncocyte completes engagement of Marcum LLP as independent auditor for FY2023

Insight Molecular Diagnostics Inc.

Marcum LLP completed client acceptance procedures on October 10, 2023, satisfying the condition noted in the original 8-K.
Marcum provided a fully executed engagement letter, formalizing its appointment as auditor for FY2023.
No other changes from the previously reported auditor change; this amendment solely confirms the completion of the engagement process.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Insight Molecular Diagnostics Inc. engaged Marcum LLP as its auditor.

Action: engagement
Auditor: Marcum LLP

Exact text from the filing

the Company is filing this amendment to the above-referenced Form 8-K to disclose that on October 10, 2023, Marcum completed its client acceptance procedures and provided the Company with a fully executed engagement letter.

View on SEC.gov

Browse all auditor changes →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-036768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.